| Mucins as differentiation markers in bronchial epithelium: squamous cell carcinoma and adenocarcinoma display similar expression patterns A Lopez-Ferrer, V Curull, C Barranco, M Garrido, J Lloreta, FX Real, ... American journal of respiratory cell and molecular biology 24 (1), 22-29, 2001 | 106 | 2001 |
| Role of fucosyltransferases in the association between apomucin and Lewis antigen expression in normal and malignant gastric epithelium A Lopez-Ferrer, C De Bolos, C Barranco, M Garrido, J Isern, I Carlstedt, ... Gut 47 (3), 349-356, 2000 | 99 | 2000 |
| ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): a retrospective observational study on biologic drug survival in daily practice E Vilarrasa, J Notario, X Bordas, A López-Ferrer, IJ Gich, L Puig Journal of the American Academy of Dermatology 74 (6), 1066-1072, 2016 | 85 | 2016 |
| Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain J Notario, G Deza, E Vilarrasa, F Valentí, C Muñoz, J Mollet, V Rocamora, ... Journal of Dermatological Treatment 30 (5), 424-429, 2019 | 74 | 2019 |
| Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review L Puig, CE Morales-Múnera, A López-Ferrer, C Geli Dermatology 225 (1), 14-17, 2012 | 70 | 2012 |
| Initial results of ixekizumab efficacy and safety in real‐world plaque psoriasis patients: a multicentre retrospective study G Deza, J Notario, A Lopez‐Ferrer, E Vilarrasa, M Ferran, E Del Alcazar, ... Journal of the European Academy of Dermatology and Venereology 33 (3), 553-559, 2019 | 59 | 2019 |
| Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre A López‐Ferrer, E Vilarrasa, IJ Gich, L Puig British Journal of Dermatology 169 (5), 1141-1147, 2013 | 57 | 2013 |
| Redefining the therapeutic objective in psoriatic patients candidates for biological therapy G Carretero, L Puig, JM Carrascosa, L Ferrándiz, R Ruiz-Villaverde, ... Journal of Dermatological Treatment 29 (4), 334-346, 2018 | 54 | 2018 |
| Role of sialyltransferases involved in the biosynthesis of Lewis antigens in human pancreatic tumour cells R Peracaula, G Tabarés, A López-Ferrer, R Brossmer, C de Bolós, ... Glycoconjugate journal 22, 135-144, 2005 | 54 | 2005 |
| Regulation of mucin and glycoconjugate expression: from normal epithelium to gastric tumors C de Bolos, FX Real, A Lopez-Ferrer Front Biosci 6 (3), 1256-63, 2001 | 49 | 2001 |
| MUC4 expression is increased in dysplastic cervical disorders A López-Ferrer, F Alameda, C Barranco, M Garrido, C De Bolós Human pathology 32 (11), 1197-1202, 2001 | 47 | 2001 |
| Differences in the O-glycosylation patterns between lung squamous cell carcinoma and adenocarcinoma A Lopez-Ferrer, C Barranco, C de Bolós American journal of clinical pathology 118 (5), 749-755, 2002 | 43 | 2002 |
| Long‐term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions J Spertino, A Lopez‐Ferrer, E Vilarrasa, L Puig Journal of the European Academy of Dermatology and Venereology 28 (11), 1514 …, 2014 | 39 | 2014 |
| The safety of ustekinumab for the treatment of psoriatic arthritis A López-Ferrer, A Laiz, L Puig Expert Opinion on Drug Safety 16 (6), 733-742, 2017 | 38 | 2017 |
| Changes in the invasive and metastatic capacities of HT‐29/M3 cells induced by the expression of fucosyltransferase 1 R Mejías‐Luque, A López‐Ferrer, M Garrido, À Fabra, C De Bolós Cancer science 98 (7), 1000-1005, 2007 | 35 | 2007 |
| Biosimilars for the treatment of psoriasis L Puig, A Lopez-Ferrer Expert Opinion on Biological Therapy 19 (10), 993-1000, 2019 | 34 | 2019 |
| Botulinum toxin A for the treatment of familial benign pemphigus A López-Ferrer, A Alomar Actas Dermo-Sifiliográficas (English Edition) 103 (6), 532-535, 2012 | 34 | 2012 |
| Mucins and mucin-associated carbohydrate antigens expression in gastric carcinoma cell lines F Carvalho, L David, JP Aubert, A López-Ferrer, C De Bolós, CA Reis, ... Virchows Archiv 435, 479-485, 1999 | 31 | 1999 |
| Real‐world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis H Iznardo, E Vilarrasa, A López‐Ferrer, L Puig British Journal of Dermatology 185 (3), 660-662, 2021 | 26 | 2021 |
| Real‐world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group E Del Alcázar, JA Suárez‐Pérez, S Armesto, R Rivera, E Herrera‐Acosta, ... Journal of the European Academy of Dermatology and Venereology 34 (12), 2821 …, 2020 | 25 | 2020 |
